JPMorgan raised the firm’s price target on Ascendis Pharma (ASND) to $200 from $168 and keeps an Overweight rating on the shares. The firm increased Yorvipath projections following the Phase III results from competitor eneboparatide in hypoparathyroidism. The analyst came away from the data even more confident in Yorvi’s trajectory and with a strong early launch it sees an over EUR 2B sales opportunity.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ASND:
- Bullish Outlook for Ascendis Pharma’s Yorvipath Amid Competitive Edge in Hypoparathyroidism Market
- Ascendis Pharma’s Market Strength and Positive Trial Outcomes Drive Buy Rating
- Ascendis Pharma Grants Employee Warrants to Strengthen Retention
- Ascendis Pharma’s Promising Outlook: Buy Rating Backed by Yorvipath Launch and TransCon CNP Potential
- Optimistic Buy Rating for Ascendis Pharma Amid Competitive Landscape in HypoPTH Market